Register for our free email digests:
Highly positive top-line weight loss results for Novo Nordisk's new GLP-1 agonist semaglutide are propelling it into Phase III trials next year for the notoriously tricky indication. The product is currently under review for type 2 diabetes.
AbbVie and Gilead have won positive recommendations in Europe and matching eight-week dosing labels for their latest hepatitis C combination therapies, Maviret and Vosevi – now it's all about the price.
How the pharmaceutical industry can use a novel US military technique to hone critical decision making strategies and to underpin M&A target screening.
Portola prepares to launch new anticoagulant betrixaban in niche patient population of patients with acute medical illness at risk of VTE, following FDA approval, despite mixed Phase III data.
Recent Tweets from Scrip
Tweets from https://twitter.com/IBI_Tweets/lists/scrip-tweets
Commercial Explore this Topic
Lupin’s founder and chairman, Desh Bandhu Gupta, who died aged 79 on June 26, was known to give employees significant autonomy at the workplace, with some saying that people were the crux of his company-building mantra.
P&G's activist investor Trian Fund Management is known for pressuring big companies to break up. The OTC business would likely have plenty of potential buyers.
Latest From Commercial
Sander Slootweg, managing partner and co-founder of Forbion Capital Partners, talks venture capital trends, industrial changes to watch, deal making and challenges faced during his years investing in the life science industry in the latest instalment of Scrip's executive profile series.
BIO International 2017 discussion: growing a biotech business. This content was produced by Scrip alongside a sponsored project with MSP, a provider of specialized science campuses in Manchester and Cheshire, UK.
Shares in India’s Fortis Hospital chain slide after Malaysia’s IHH Healthcare denies it is close to a purchase from cash-strapped tycoons Malvinder and Shivinder Singh, who continue to fight an arbitration order to pay hundreds of millions of dollars in compensation to Daiichi Sankyo over Ranbaxy.
Pfizer and Cipla have separately committed to expanding access to affordable oncology drugs in sub-Saharan Africa in collaboration with the American Cancer Society and the Clinton Health Access Initiative. The public-private alliances are expected to enable procurement of these medicines for the African nations at significant savings, which Cipla tells Scrip could be in the region of 20-30% initially.
Merck of Germany's oral multiple sclerosis medicine cladribine looks set to finally get EU approval. But the long, slow race it has had to endure - and time lost getting there - may curb sales.
Cadila Healthcare, the listed flagship of billionaire Pankaj Patel’s Zydus Group, has become India’s second most valuable pharmaceutical firm after its shares were lifted by the resolution of US regulatory issues engulfing its biggest manufacturing plant, and a string of drug approvals.
Policy & Regulation Explore this Topic
Kamada has withdrawn its European approval application for an inhaled version of its emphysema drug Glassia – a move that shocked investors because of the company's continued insistence data from a failed pivotal study would be enough to convince regulators.
The EU’s CHMP has given the green light to Imraldi, Samsung Bioepis’ biosimilar version of AbbVie’s blockbuster adalimumab product Humira. If approved by the European Commission, this will be the South Korean company’s third biosimilar anti-TNF alpha product to gain a marketing authorization in the EU.
The likely upcoming EU approval of Kisqali, Novartis' answer to Pfizer's Ibrance, opens a new front in a breast cancer marketing battle that is likely to get more intense.
Melinta is positioning its novel fluroquinolone antibiotic as an attractive option for seriously ill patients with underlying chronic conditions, but Baxdela will face challenges in a market dominated by generics.
Research & Development Explore this Topic
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Latest From Research & Development
Over the last week bluebird bio has reported first interim Phase III data from the Northstar-2 trial of blood disease drug LentiGlobin and announced a public offering of $350m of common stock.
NEJM editorial suggests that differences in PD-L1 testing may explain why Bristol's Opdivo failed in first-line lung cancer trial whereas Merck's Keytruda succeeded, but some analysts aren't so sure.
Belgium’s ASIT biotech hopes to succeed in the difficult allergy market with a more focused Phase III study of its grass pollen allergy product, after its first Phase III study showed that the product significantly improved symptoms, but not to an extent to satisfy regulators.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.